At PromiseCare Medical Group in Hemet, California, patients diagnosed with head or neck cancer have access to a range of treatment options, including Transoral Robotic Surgery (TORS).
This minimally invasive technique utilizes a robotic system to remove tumors through the mouth, preserving speech and swallowing abilities. By choosing TORS, patients can reduce their risk of long-term swallowing problems and shorten their hospital stay.
PromiseCare Medical Group’s medical team has achieved significant success rates and better outcomes with TORS, revolutionizing the treatment of head and neck cancers.
Recognizing TORS’s advantages and drawbacks enables patients to make a more informed choice about their treatment.
Overview
When facing a diagnosis of head or neck cancer, understanding treatment options is essential. One option to consider is Transoral Robotic Surgery (TORS), a minimally invasive technique that’s changing the game for head and neck cancers.
Created in the early 2000s, TORS has established a new standard of care that provides substantial advantages over conventional surgery.
With TORS, surgeons use a robotic system with a high-definition 3D camera and multi-jointed instruments. These instruments enable precise manipulation in confined spaces, thereby enhancing surgical precision and visualization.
The procedure is performed through the mouth, reducing recovery time, complications, and postoperative pain.
After successful clinical trials demonstrated improved treatment outcomes, TORS gained FDA approval in 2009.
By choosing TORS, patients can return to normal activities quicker, thanks to its minimally invasive approach.
When navigating treatment options, considering the benefits of TORS can help improve quality of life.
Types
Transoral Robotic Surgery (TORS) encompasses various types for treating head and neck cancers. TORS primarily focuses on treating oropharyngeal, hypopharyngeal, and laryngeal cancers, benign tumors, and obstructive sleep apnea. This robotic-assisted surgery utilizes a surgical system that allows for minimally invasive access through the mouth.
Since its approval in 2009, TORS has broadened its scope to incorporate specialized applications. It is currently utilized for managing unknown primary tumors and performing supraglottic laryngectomies in cases of laryngeal cancer. TORS establishes a new standard of care for head and neck cancers, demonstrating comparable oncologic outcomes to conventional techniques while reducing complications.
The technique’s precision and reduced operating times, typically 1.5 to 2 hours, make it an attractive option for patients seeking effective and efficient treatment.
Investigating TORS showcases its flexibility and advantages in head and neck surgery. Notably, its effects on oropharyngeal cancers have been remarkable, providing patients with a minimally invasive option that yields encouraging outcomes.
Why it’s done
Transoral robotic surgery (TORS) is performed to effectively treat neck cancer and benign tumors. This innovative surgery allows for the removal of tumors through the mouth, minimizing incisions and postoperative pain.
TORS is now a standard treatment for mouth and throat cancer, as it effectively preserves speech and swallowing abilities, which are essential for maintaining a good quality of life.
Employing TORS enables intricate procedures to be carried out with smaller incisions, lowering both recovery time and the likelihood of complications. This surgical method is also effective in addressing obstructive sleep apnea, which is often caused by a swollen tongue base that obstructs the airway.
Enhanced visualization and access to difficult areas provide better functional outcomes.
TORS offers a promising treatment option for thousands of people diagnosed with head and neck cancers every year. It has been established as an effective treatment method since receiving FDA approval in 2009.
The benefits of TORS include minimizing incisions and postoperative pain, preserving speech and swallowing capabilities, and reducing recovery time and the risk of complications.
Who it’s for
People diagnosed with head and neck cancers, particularly those with oropharyngeal, hypopharyngeal, or laryngeal cancer in the early stages, may benefit from transoral robotic surgery (TORS).
Suitability for TORS is determined by evaluating overall health, the extent of cancer spread, and anatomical factors affecting access to the tumor. Staging endoscopy may be part of this assessment.
TORS offers several benefits as a minimally invasive option. It often results in fewer long-term swallowing problems and lower risks of complications compared to traditional surgical approaches.
Additionally, TORS can lead to quicker recovery times and shorter hospital stays. For those seeking a less invasive alternative to traditional neck dissection, TORS may be a viable option.
While primarily used for cancer treatment, TORS is also being explored as a treatment option for patients with obstructive sleep apnea related to airway obstruction caused by a large tongue base.
Risks
When considering transoral robotic surgery as a treatment option, it is essential to balance its benefits with potential drawbacks. Although TORS typically has fewer complications than conventional open surgery, risks must be taken into account. These risks include bleeding, infection, and damage to nearby tissues or nerves during the procedure.
The space between the posterior pharyngeal wall and the hyoid can restrict surgical access, rendering TORS a less viable choice for certain patients. While the loss of tactile feedback during robotic surgery can hinder the surgeon’s evaluation of tissue texture, improved visual information tends to mitigate this drawback.
Short-term postoperative complications, including temporary dysphagia or voice changes, may occur, but these often improve over time. Discussing these potential side effects with a healthcare provider is essential to understand the risks and benefits of TORS.
Research on long-term functional outcomes after TORS is ongoing, necessitating further studies to confirm its efficacy and reveal any possible disadvantages compared to conventional approaches. Recognizing the associated risks is crucial for making an informed decision about the appropriateness of TORS as a treatment option.
How you prepare
Preparing for Transoral Robotic Surgery (TORS) involves a comprehensive and collaborative strategy to ensure readiness for the procedure. The process begins with an initial office examination to establish eligibility for the surgery. This assessment might include staging endoscopy to evaluate how far the cancer has progressed. Even if earlier evaluations were conducted, further endoscopies may be required to ensure a comprehensive understanding of the situation.
Preparation may also involve imaging scans, swallow evaluations, and consultations with a speech-language pathologist. These assessments help evaluate readiness for the procedure and identify potential issues that may arise.
To ensure optimal conditions for anesthesia, dietary guidelines must be adhered to before surgery. It’s crucial to discuss any concerns and your overall health with a healthcare provider to ensure informed consent and adequate preparation for the surgery.
What you can expect
When undergoing transoral robotic surgery, a significantly shorter procedure can be expected compared to traditional open surgery. This type of surgery typically lasts between 1.5 and 2 hours, whereas conventional surgery can take 10-12 hours. The significant reduction in surgery time is partly due to the advanced technology used, including a high-definition 3D camera and robotic arms that enable precise tumor resection.
Patients may experience reduced post-operative discomfort and can eat and drink as soon as the day following surgery. Additionally, the hospital stay is shorter, generally around 2 days, unlike the 7-15 days required for traditional methods.
During and after the procedure, the following can be expected:
- The robotic arms allow for precise dissection and tumor removal, reducing the risk of complications.
- Access to extensive support services, including rehabilitation and speech therapy, aids in recovery.
- Follow-up care is essential, with scheduled visits to monitor recovery and prevent cancer recurrence, ensuring the best possible care after the procedure.
Results
Numerous studies highlighting its effectiveness in treating oropharyngeal squamous cell carcinoma support the success of transoral robotic surgery. Research indicates encouraging outcomes.
With transoral robotic surgery (TORS), overall survival rates range from 81-100% and disease-free survival rates from 85.7-96%. Additionally, TORS reduces morbidity, leading to improved functional outcomes in swallowing and speech.
Comparatively, TORS patients often experience better swallowing abilities – with 74% of patients eating as well as ever at 12 months – compared to traditional treatments. TORS also reduces the need for postoperative interventions like radiation or chemotherapy, resulting in lower long-term treatment requirements.
TORS patients have been shown to have comparable survival rates and better functional outcomes than patients receiving primary radiation therapy. These results indicate that TORS is a highly effective oropharyngeal squamous cell carcinoma treatment, offering improved quality of life and reduced treatment burdens.
Patients must discuss these findings with their healthcare professionals when considering treatment options for this condition.